Program
ABSK061
A development code. Also written as “ABSK061 + ABSK043” and “ABSK061+ABSK043 in combination with CAPOX”.
Its studies are mostly in Achondroplasia · Carcinoma, Transitional Cell, led by Abbisko Cayman.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbisko Cayman | 43 open or running | phase 2since Oct 1, 2024 | Jan 12, 2022 | Dec 15, 2028phase 2 · NCT07297875 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 12, 2022First study: phase 1 study in Solid TumorFirst studyNCT05244551 · 85 planned · United States, China
- Oct 1, 2024Phase 2 study in Carcinoma, Transitional CellNCT06632262 · 202 planned · China
- May 14, 2025Phase 1 study in HealthyNCT07007546 · 42 enrolled · China
- Nov 24, 2025Phase 2 study in AchondroplasiaNCT07297875 · 110 planned · China
Ahead
- Dec 15, 2028Primary completion: phase 2 study in AchondroplasiaNCT07297875
- Nov 30, 2029Primary completion: phase 2 study in Carcinoma, Transitional CellNCT06632262
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07297875Achondroplasia · China | 2 | Not yet recruiting | Dec 15, 2028 | 110 |
| NCT07007546Healthy · China | 1 | Completed | Jul 30, 2025 | 42 |
| NCT06632262Carcinoma, Transitional Cell · China | 2 | Recruiting | Nov 30, 2029 | 202 |
| NCT05244551Solid Tumor · United States, China | 1 | Recruiting | Apr 30, 2025 | 85 |
How it is read
Names in the registry
- “ABSK061”, 5 entries
- “ABSK061 + ABSK043”, 1 entry
- “ABSK061+ABSK043 in combination with CAPOX”, 1 entry
Codes read as this program: ABSK061.
Conditions, from the studies’ own filings
- Achondroplasia, 1 study
- Carcinoma, Transitional Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.